A Phase 3 interventional study of Placebo and Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Colorectal Neoplasms and Neoplasm Metastasis, sponsored by Sanofi. Completed at 221 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-28.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one has the largest enrollment, is the only one that started in 2007, is one of 4 in phase 3, and was the 1st registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,226 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 63 across the 24 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 24 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
24 studies in Colorectal Neoplasms by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 24 studies in Colorectal Neoplasms by Sanofi, this one has the largest enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2007, is one of 10 in phase 3, and was the 10th registered.
Sanofi’s Colorectal Neoplasms studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing aflibercept in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 24 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease.
The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.
Participants were
The criteria for discontinuation of study treatment for a participant are:
the investigator thought that continuation of the study would be detrimental to the participants well-being due to
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who met the following main selection criteria were included in the study.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
Drug: Placebo · Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) · Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours
The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Overall Survival (OS)
Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011). OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.
Time frame: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC. PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model. The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred.
Time frame: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria
The overall ORR was the percentage of evaluable participants who achieved complete response \[CR\] or partial response \[PR\] according to RECIST criteria version 1.0. * CR reflected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined reduction in tumor burden Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.
Time frame: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
Number of Participants With Adverse Events (AE)
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
Time frame: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay.
Time frame: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
Between 19 November 2007 and 16 March 2010, 614 participants were randomized to the placebo arm and 612 participants were randomized to the aflibercept arm.
| Milestone | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| Started | 614 | 612 |
| Treated | 609 | 607 |
| Safety population | 605 | 611 |
| Ongoing treatment | 11 | 14 |
| Completed | 0 | 0 |
| Not completed | 614 | 612 |
| Withdrew: Adverse event | 74 | 163 |
| Withdrew: Disease progression | 437 | 305 |
| Withdrew: Poor compliance to protocol | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Physician decision | 21 | 20 |
| Withdrew: Consent withdrawn | 2 | 6 |
| Withdrew: Subject request | 43 | 77 |
| Withdrew: Metastatic surgery | 10 | 12 |
| Withdrew: Unauthorized procedure | 3 | 1 |
| Withdrew: Randomized but not treated | 5 | 5 |
| Withdrew: Missed visit window | 1 | 4 |
| Withdrew: Planning surgery | 1 | 1 |
| Withdrew: Ongoing treatment | 11 | 14 |
Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011). OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.
| months | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| Overall Survival (OS) | 12.06 (6.83 to 21.03) | 13.50 (7.62 to 25.59) |
PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC. PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model. The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred.
| months | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) | 4.67 (2.60 to 9.10) | 6.90 (3.84 to 10.05) |
The overall ORR was the percentage of evaluable participants who achieved complete response \[CR\] or partial response \[PR\] according to RECIST criteria version 1.0. * CR reflected the disappearance of all tumor lesions (with no new tumors) * PR reflected a pre-defined reduction in tumor burden Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.
| percentage of participants | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria | 11.1 (8.5 to 13.8) | 19.8 (16.4 to 23.2) |
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
| participants | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | 592 | 606 |
| Serious TEAE | 198 | 294 |
| TEAE leading to Death | 29 | 37 |
| TEAE causing permanent treatment discontinuation | 73 | 164 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay.
| participants | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| At least one positive sample in the ADA assay | 18 | 8 |
| At least one positive sample in the NAb assay | 2 | 1 |
Collected over From treatment initiation to 7 February, 2011. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/FOLFIRI | — | 198/605 (32.7%) | 575/605 (95%) |
| Aflibercept/FOLFIRI | — | 294/611 (48.1%) | 599/611 (98%) |
| Event | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 14/605 | 44/611 |
| DehydrationMetabolism and nutrition disorders | 7/605 | 24/611 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/605 | 19/611 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 12/605 | 19/611 |
| Disease progressionGeneral disorders | 14/605 | 16/611 |
| PyrexiaGeneral disorders | 15/605 | 10/611 |
| Abdominal painGastrointestinal disorders | 7/605 | 12/611 |
| Intestinal obstructionGastrointestinal disorders | 11/605 | 10/611 |
| PneumoniaInfections and infestations | 5/605 | 11/611 |
| NeutropeniaBlood and lymphatic system disorders | 4/605 | 11/611 |
| Event | Placebo/FOLFIRI | Aflibercept/FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 335/605 | 411/611 |
| NauseaGastrointestinal disorders | 327/605 | 322/611 |
| StomatitisGastrointestinal disorders | 199/605 | 304/611 |
| FatigueGeneral disorders | 234/605 | 292/611 |
| HypertensionVascular disorders | 65/605 | 250/611 |
| NeutropeniaBlood and lymphatic system disorders | 202/605 | 229/611 |
| VomitingGastrointestinal disorders | 199/605 | 194/611 |
| Decreased appetiteMetabolism and nutrition disorders | 143/605 | 195/611 |
| Weight decreasedInvestigations | 87/605 | 195/611 |
| AlopeciaSkin and subcutaneous tissue disorders | 182/605 | 164/611 |
| Age Continuous(years) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| Mean | 60.2 ± 10.8 | 59.5 ± 10.5 | 59.8 ± 10.7 |
| Age, Customized(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| <65 years | 376 | 407 | 783 |
| >=65 but <75 years | 199 | 172 | 371 |
| >=75 years | 39 | 33 | 72 |
| Sex/Gender, Customized(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| Male | 353 | 365 | 718 |
| Female | 261 | 247 | 508 |
| Race/Ethnicity, Customized(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| Caucasian/White | 523 | 548 | 1071 |
| Black | 27 | 16 | 43 |
| Asian/Oriental | 51 | 35 | 86 |
| Other | 13 | 13 | 26 |
| Region of Enrollment(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| ARGENTINA | 4 | 2 | 6 |
| AUSTRALIA | 42 | 54 | 96 |
| AUSTRIA | 3 | 4 | 7 |
| BELGIUM | 37 | 45 | 82 |
| BRAZIL | 21 | 27 | 48 |
| CHILE | 31 | 33 | 64 |
| CZECH REPUBLIC | 30 | 47 | 77 |
| DENMARK | 9 | 6 | 15 |
| ESTONIA | 7 | 3 | 10 |
| FRANCE | 1 | 1 | 2 |
| GERMANY | 23 | 12 | 35 |
| GREECE | 9 | 10 | 19 |
| ITALY | 26 | 23 | 49 |
| KOREA, REPUBLIC OF | 39 | 26 | 65 |
| NETHERLANDS | 20 | 14 | 34 |
| NEW ZEALAND | 13 | 7 | 20 |
| NORWAY | 14 | 19 | 33 |
| POLAND | 24 | 32 | 56 |
| PUERTO RICO | 4 | 2 | 6 |
| ROMANIA | 16 | 16 | 32 |
| RUSSIAN FEDERATION | 35 | 40 | 75 |
| SOUTH AFRICA | 36 | 31 | 67 |
| SPAIN | 27 | 28 | 55 |
| SWEDEN | 10 | 4 | 14 |
| TURKEY | 4 | 2 | 6 |
| UKRAINE | 11 | 11 | 22 |
| UNITED KINGDOM | 47 | 52 | 99 |
| UNITED STATES | 71 | 61 | 132 |
| Eastern Cooperative Oncology Group (ECOG) performance status score(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| Participants with ECOG Score = 0 | 350 | 349 | 699 |
| Participants with ECOG Score = 1 | 250 | 250 | 500 |
| Participants with ECOG Score = 2 | 14 | 13 | 27 |
| Prior Bevacizumab(participants) | Placebo/Folfiri | Aflibercept/Folfiri | Total |
|---|---|---|---|
| Yes | 187 | 186 | 373 |
| No | 427 | 426 | 853 |
Showing the first 100 of 221 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2007, a primary completion of Feb 2011 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 7 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept